Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2018

Revenue From Contract With Customer [Abstract]

Disaggregated Revenues by Timing of Transfer of Goods or Services

The following table presents our revenues, disaggregated by timing of transfer of goods or services (in thousands):

	Three Months Ended September 30, 2018						Nine Months Ended September 30, 2018
	Product Revenue, net		Collaboration and License Revenue		Total		Product Revenue, net		Collaboration and License Revenue		Total
Timing of revenue recognition:
Transferred at a point in time	$	7,176	$	—	$	7,176	$	10,047	$	—	$	10,047
Transferred over time		—		7,001		7,001		—		14,785		14,785
Total	$	7,176	$	7,001	$	14,177	$	10,047	$	14,785	$	24,832

Schedule of Changes in Contract Assets and Liabilities

The following table presents changes in our contract assets and liabilities for the nine months ended September 30, 2018 (in thousands):

	Balance at Beginning of Period		Addition		Deduction			Balance at End of Period
Contract assets:
Unbilled - collaboration and license revenue	$	6,694	$	10,348	$	(7,170	)	$	9,872
Total contract assets	$	6,694	$	10,348	$	(7,170	)	$	9,872
Contract liabilities:
Deferred revenue	$	7,623	$	6,857	$	(7,037	)	$	7,443
Total contract liabilities	$	7,623	$	6,857	$	(7,037	)	$	7,443

Significant changes in the contract assets and contract liabilities balances during the periods are as follows (in thousands):

	Three Months Ended as of September 30, 2018		Nine Months Ended as of September 30, 2018
Cumulative catch-up adjustment to revenue related to a change in an estimate of the transaction price	$	2,765	$	4,746
Revenue recognized according to the current period performance that was included in the contract liability at the beginning of the period		2,092		6,124

Estimated Revenue Expected to be Recognized in Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of September 30, 2018 (in thousands):

Collaborator	Transaction Price Allocated to the Remaining Performance Obligation as of September 30, 2018		Expected Year By Which Revenue Recognition Will Be Completed		Percentage of Revenue Recognized
BMS and Pfizer - 2014 agreement	$	78		2019		99	%
BMS and Pfizer - 2016 agreement		1,900		2021		85	%
Daiichi Sankyo - 2014 agreement		1,951		2020		94	%
Daiichi Sankyo - 2016 agreement		3,974		2023		74	%
Bayer and Janssen - 2014 agreement		122		2019		99	%
Bayer - 2016 agreement		3,547		2023		77	%
Total	$	11,572